[Archived Hypothesis]

Target: %s Composite Score: 0.300 Price: $0.30 Citation Quality: Pending Status: archived
☰ Compare⚛ Collideinteract with this hypothesis
⚠ Missing Evidence⚠ No Target Gene⚠ Thin Description⚠ Low Validation Senate Quality Gates →
Evidence Strength Pending (0%)
0
Citations
1
Debates
3
Supporting
0
Opposing
Quality Report Card click to collapse
D
Composite: 0.300
Top 91% of 1512 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
F Mech. Plausibility 15% 0.00 Top 50%
F Evidence Strength 15% 0.00 Top 50%
F Novelty 12% 0.00 Top 50%
F Feasibility 12% 0.00 Top 50%
F Impact 12% 0.00 Top 50%
F Druggability 10% 0.00 Top 50%
F Safety Profile 8% 0.00 Top 50%
F Competition 6% 0.00 Top 50%
F Data Availability 5% 0.00 Top 50%
F Reproducibility 5% 0.00 Top 50%
Evidence
3 supporting | 0 opposing
Citation quality: 0%
Debates
1 session A
Avg quality: 0.81

From Analysis:

Legacy Pre-Pipeline Hypothesis Import

Hypotheses created before the analysis pipeline was established (pre-2026-04-01)

→ View full analysis & debate transcript

Description

No description available

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.00 (15%) Evidence 0.00 (15%) Novelty 0.00 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.50 (8%) 0.300 composite
3 citations 3 with PMID Validation: 0% 3 supporting / 0 opposing
For (3)
No supporting evidence
No opposing evidence
(0) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
2
1
MECH 2CLIN 0GENE 1EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
No claimSupportingMECHAutophagy-2023-PMID:37469132-
No claimSupportingGENEFront Cell Dev …-2022-PMID:35874822-
No claimSupportingMECHJ Alzheimers Di…-2010-PMID:20442495-
Legacy Card View — expandable citation cards

Supporting Evidence 3

No claim
Autophagy · 2023 · PMID:37469132
No claim
Front Cell Dev Biol · 2022 · PMID:35874822
No claim
J Alzheimers Dis · 2010 · PMID:20442495

Opposing Evidence 0

No evidence recorded
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Legacy Pre-Pipeline Hypotheses: Neurodegeneration

Hypothesis 1: Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkinson's Disease

Mechanism: Misfolded α-synuclein (aSyn) aggregates are transmitted via exosomes from donor to recipient neurons, templating endogenous aSyn misfolding through a "prion-like" mechanism. This explains the stereotypical progression of Lewy pathology in Braak staging.

Target: RAB27A (exosome biogenesis), GBA (lysosomal function), LRRK2 G2019S (enhances exosome release)

Supporting Evidence:

  • Braak et al. (2003) Neurobiology of

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Critical Evaluation of Legacy Pre-Pipeline Hypotheses

General Methodological Concerns (Cross-Cutting Issues)

Before evaluating individual hypotheses, several systemic weaknesses affect the entire corpus:

1. Animal Model Validity Crisis
All seven hypotheses rely heavily on transgenic mouse models (5xFAD, MPTP, α-syn transgenic mice) with well-documented limitations:

  • Mouse neuroimmune systems differ substantially from humans
  • Accelerated pathology timelines may not reflect human disease etiology
  • Many therapeutic candidates successful in rodents have failed in human trials (anti-

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Comprehensive Feasibility Assessment: Legacy Neurodegeneration Hypotheses

Preamble

This assessment evaluates each hypothesis across five critical domains using a standardized framework. Evidence strength, translational readiness, and development feasibility are rated on consistent scales to enable cross-hypothesis comparison. Where the Skeptic's revised confidence scores diverge from my independent assessment, I note the discrepancy and rationale.

Evaluation Framework

| Domain | Assessment Criteria |
|--------|---------------------|
| Druggability | Target tractability, ch

Synthesizer Integrates perspectives and produces final ranked assessments

Price History

0.130.260.40 debate: market_dynamics (2026-04-16T09:29)score_update: market_dynamics (2026-04-16T13:16)score_update: market_dynamics (2026-04-16T13:31)evidence: market_dynamics (2026-04-16T13:43)evidence: market_dynamics (2026-04-16T13:54)evidence: market_dynamics (2026-04-16T16:22)debate: market_dynamics (2026-04-16T17:48)score_update: market_dynamics (2026-04-16T19:54)debate: market_dynamics (2026-04-16T20:43) 0.53 0.00 2026-04-162026-04-162026-04-22 Market PriceScoreevidencedebate 17 events
7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.8492
Events (7d)
4
⚡ Price Movement Log Recent 9 events
Event Price Change Source Time
💬 Debate Round $0.450 ▲ 33.5% market_dynamics 2026-04-16 20:43
📊 Score Update $0.337 ▲ 148.1% market_dynamics 2026-04-16 19:54
💬 Debate Round $0.136 ▼ 73.2% market_dynamics 2026-04-16 17:48
📄 New Evidence $0.507 ▲ 189.0% market_dynamics 2026-04-16 16:22
📄 New Evidence $0.176 ▲ 164.1% market_dynamics 2026-04-16 13:54
📄 New Evidence $0.067 ▼ 60.3% market_dynamics 2026-04-16 13:43
📊 Score Update $0.168 ▼ 45.4% market_dynamics 2026-04-16 13:31
📊 Score Update $0.307 ▲ 184.1% market_dynamics 2026-04-16 13:16
💬 Debate Round $0.108 market_dynamics 2026-04-16 09:29

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (3)

Mitochondrial dysfunction in Parkinson's disease.
Journal of Alzheimer's disease : JAD (2010) · PMID:20442495
No extracted figures yet
Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson's Disease.
Frontiers in cell and developmental biology (2022) · PMID:35874822
No extracted figures yet
No extracted figures yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

High Efficiency Resource Efficiency Score
1.00
93.6th percentile (760 hypotheses)
Tokens Used
1
KG Edges Generated
0
Citations Produced
0

Cost Ratios

Cost per KG Edge
1.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
1.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
5.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.100
10% weight of efficiency score
Adjusted Composite
0.400

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Related Hypotheses

No related hypotheses found

Estimated Development

Estimated Cost
$2M
Timeline
2.0 years

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

Source Analysis

Legacy Pre-Pipeline Hypothesis Import

neurodegeneration | 2025-12-31 | archived

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alz
Score: 0.82 · TREM2
Complement C1q-Mediated Synaptic Pruning Drives Early Cognitive Declin
Score: 0.77 · C1Q
C9orf72 Hexanucleotide Repeat Dipeptide Repeat Proteins Inhibit Nucleo
Score: 0.74 · NUP98
c-Abl Tyrosine Kinase Activation Drives α-Synuclein Phosphorylation an
Score: 0.60 · ABL1
Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkins
Score: 0.59 · RAB27A
→ View all analysis hypotheses